The inflammatory gene pathway is not a major contributor to polycystic ovary snydrome

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages

  Bhatt, Surabhi ^a   Mutharasan, Priscilla ^a   Garcia, Obed A ^a   Jafari, Nadereh ^a   Legro, Richard S ^b   Dunaif, Andrea ^a   Urbanek, Margrit ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; TESTOSTERONE;

AKT2; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; IKBKG GENE; IRF 1 GENE; MAJOR CLINICAL STUDY; MAP3K7 GENE; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM; TNFRS11A GENE; TRIACYLGLYCEROL BLOOD LEVEL;

CASE-CONTROL STUDIES; CHOLESTEROL, HDL; ENDOTHELIN-1; FEMALE; GENE FREQUENCY; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; SIGNAL TRANSDUCTION;

EID: 84895824547     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2342     Document Type: Article

References (31)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-2749. (Pubitemid 38766360)
2. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992:377-384.
3. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981-1030.
4. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5:551-559. (Pubitemid 40684652)
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-867. (Pubitemid 46024993)
6. Duleba AJ, Dokras A. Is PCOS an inflammatory process? Fertil Steril. 2012;97:7-12.
7. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millán JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia. 2003;46:625-633. (Pubitemid 36808182)
8. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86:2453-2455. (Pubitemid 32545690)
9. Escobar-Morreale HF, Calvo RM, Sancho J, San Millan JL. TNF-α and hyperandrogenism: a clinical, biochemical, and molecular genetic study. J Clin Endocrinol Metab. 2001;86:3761-3767. (Pubitemid 32755973)
10. Tarkun I, Arslan BC, Cantürk Z, Türemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89:5592-5596. (Pubitemid 39518445)
11. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab. 2005;90:6014-6021. (Pubitemid 41606519)
12. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:1048-1058.e1-e2.
13. Perry JR, Weedon MN, Langenberg C, et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet. 2010;19:535-544.
14. Mutharasan P, Galdones E, Peñalver Berñabé B, et al. Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab. 2013;98:E185-E190.
15. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998;95:14956-14960. (Pubitemid 29003738)
16. Sam S, Sung YA, Legro RS, Dunaif A. Evidence for pancreatic β-cell dysfunction in brothers of women with polycystic ovary syndrome. Metab Clin Exp. 2008;57:84-89. (Pubitemid 350234977)
17. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111:607-613. (Pubitemid 34088070)
18. Price AL, Butler J, Patterson N, et al. Discerning the ancestry of European Americans in genetic association studies. PLoS Genet. 2008;4:e236.
19. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575. (Pubitemid 47330214)
20. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Optimal designs for two-stage genome-wide association studies. Genet Epidemiol. 2007;31:776-788. (Pubitemid 350133976)
21. Luque-Ramírez M, San Millán JL, Escobar-Morreale HF. Genomic variants in polycystic ovary syndrome. Clin Chim Acta. 2006;366:14-26. (Pubitemid 43330963)
22. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55-59.
23. Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44:1020-1025.
24. Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:981-990.
25. Flannick J, Korn JM, Fontanillas P, et al. Efficiency and power as a function of sequence coverage, SNP array density, and imputation. PLoS Comput Biol. 2012;8:e1002604.
26. Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013;159:1-12.
27. Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008;1:36-43.
28. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437-446. (Pubitemid 32730790)
29. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science. 1994;265:956-959.
30. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit IκB-α phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996;156:3961-3969. (Pubitemid 26137683)
31. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science. 1996;274:1383-1385. (Pubitemid 26391464)